Investigation of the efficacy of Imeglimin on glycemic control and the underlying mechanisms
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000049203
- Lead Sponsor
- Toho university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Not provided
(1)Type 1 diabetes mellitus patients (2)Patients with severe liver disease or AST (GOT) or ALT (GPT) >100 IU/L (3)Patients with serious renal disease and patients with a serum creatinine level of 2.0 mg/dL or higher before the start of the study (4)Patients with overt heart failure and those who had myocardial infarction within 3 months before the start of the study (5)Patients with severe pancreatic disease (6)Patients with acute stage/serious condition that may cause change in condition due to blood sugar fluctuation or addition of drugs (7)Patients with serious infections or serious trauma. Patients before and after surgery (8)Patients with severe chronic bowel disease accompanied by inflammatory bowel disease, colonic ulcer, focal bowel obstruction, bowel obstruction predisposition, or digestive/absorptive disorders (9) Excessive habitual drinkers (10) Pregnant women, women who may be pregnant, women who wish to become pregnant, and women who are breastfeeding (11) Patients who are judged to be inappropriate by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method